Celsion's newest cancer treatment adds to upside

13-02-2014 Seeking AlphaComments (0)


Development of a new treatment for highly lethal brain cancer that claims the lives of up to 60% of diagnosed patients is set to start soon by Celsion Corporation (CLSN), using ThermoDox, its patented heat-activated liposomal form of the anti-cancer agent doxorubicin that has been shown to concentrate at the site of tumors. Preclinical studies to be conducted at the Harvard Medical School and the Brigham and Women's Hospital, renowned as two of the top research facilities in the country, will examine the effect of ThermoDox on glioblastoma multiforme (GBM) in conjunction with high intensity focused ultrasound (HIFU). Dr. Costas Arvanitis, PhD, trained at the Imperial College of London and a leader in ultrasound-based medicine directed

Read more on Seeking Alpha

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top